Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.51Last Year’s EPS
0.31Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: -10.88%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strategic acquisitions, particularly the acquisition of Previse and the strong performance of TissueCypher. However, challenges were noted in gross margin decline, discontinuation of IDgenetix, and reimbursement issues for DecisionDx-SCC. Despite these challenges, the positive developments appear to outweigh the negatives.Company Guidance
During the Castle Biosciences First Quarter 2025 Conference Call, the company reported a 21% revenue increase to $88 million, driven by a 33% rise in test report volume compared to the same period in 2024. The company highlighted a strong balance sheet with $275 million in cash, cash equivalents, and marketable investment securities. Castle Biosciences announced the acquisition of Previse to strengthen its position in the gastrointestinal space and reported that its DecisionDx-Melanoma test surpassed 200,000 orders. Additionally, DecisionDx-SCC delivered 4,375 test reports in Q1 2025 and TissueCypher saw a 117% growth in test reports year-over-year. The company also raised its total revenue guidance for 2025 to $287-$297 million. Adjusted gross margin was reported at 81.2%, and the company experienced a net loss of $25.8 million for the quarter.Revenue Growth
Revenue grew by 21% to $88 million, and test report volume for core revenue drivers increased by 33% compared to the first quarter of 2024.
Strong Balance Sheet
The company has a strong balance sheet with $275 million in cash, cash equivalents, and marketable investment securities.
Previse Acquisition
Castle Biosciences signed a definitive agreement to acquire Previse, enhancing its position in the gastrointestinal space.
TissueCypher Growth
TissueCypher test reports grew by 117% year-over-year, delivering 7,432 test reports in the first quarter of 2025.
DecisionDx-Melanoma Milestone
DecisionDx-Melanoma surpassed 200,000 test orders since its launch.
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $18.75 | $16.62 | -11.36% |
Feb 27, 2025 | $25.28 | $21.68 | -14.24% |
Nov 04, 2024 | $33.64 | $31.15 | -7.40% |
Aug 05, 2024 | $21.85 | $24.90 | +13.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2025 (Q2) is -0.51.